John D. Quisel, Chief Executive Officer of Disc Medicine, Inc. (NASDAQ:IRON), executed a series of sales totaling approximately $2.38 million in company shares on June 18, 2026. The transactions were facilitated under a Rule 10b5-1 trading plan established in March 2026. Prior to the sales, Mr. Quisel exercised stock options for 34,000 shares at $9.86 per share. Following these activities, his direct ownership stands at 226,064 shares. Disc Medicine continues to advance its clinical pipeline, with recent updates from the RALLY-MF trial and FDA interactions regarding bitopertin.
Form 4 filings with the Securities and Exchange Commission detail the specific mechanics of the June 18 transactions. Mr. Quisel sold 34,000 shares across multiple price points, ranging from $69.35 to $71.85 per share. The breakdown of these sales includes 22,927 shares traded between $69.35 and $70.33, 9,522 shares between $70.36 and $71.35, and 1,551 shares between $71.36 and $71.85. These sales followed the exercise of 34,000 stock options at $9.86 per share, which totaled $335,240. The options were fully vested and exercisable as of the transaction date.
All transactions were conducted under a Rule 10b5-1 trading plan adopted by Mr. Quisel on March 12, 2026. This automated trading framework allows executives to buy or sell shares at predetermined times, removing individual discretion from the process. Following these transactions, Mr. Quisel directly holds 226,064 shares of Disc Medicine common stock.
The stock currently trades at $70.45, reflecting a 37% gain over the past year. Despite this performance, InvestingPro analysis suggests the shares may be overvalued relative to its Fair Value estimate. The company's stock exhibits high volatility with a beta of 2.1. InvestingPro identifies 10 additional key insights about IRON's financial health and prospects.
In other recent news, Disc Medicine Inc. presented updated clinical trial data for two investigational treatments at the European Hematology Association Annual Meeting in Stockholm. The RALLY-MF trial involved 61 adult patients with myelofibrosis and anemia, showing promising results for the treatment DISC-0974. Additionally, Disc Medicine completed a Type A meeting with the U.S. Food and Drug Administration regarding the Complete Response Letter for bitopertin in erythropoietic protoporphyria. The FDA agreed that the ongoing Phase 3 APOLLO study could potentially support a traditional approval if successful, with a response expected by the end of 2026.
Moreover, Stifel reiterated a Buy rating and a $111.00 price target for Disc Medicine following the presentation of the RALLY-MF trial data at the ASCO meeting. The trial demonstrated efficacy in treating myelofibrosis-related anemia, regardless of baseline anemia severity. In another development, Disc Medicine launched an expanded access program for bitopertin in the U.S. This program aims to provide treatment for patients with erythropoietic protoporphyria and X-linked protoporphyria who have no satisfactory therapeutic alternatives. Furthermore, Disc Medicine announced plans to present additional data from the RALLY-MF Phase 2 trial at the upcoming American Society of Clinical Oncology Annual Meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Should you invest $2,000 in IRON right now?ProPicks AI evaluates IRON alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if IRON is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?See More Stocks